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Abstract
Colorectal cancer (CRC), the second most common cancer globally, resulted in 881,000 deaths in 2018. Toll-like receptors
(TLRs) are crucial to detecting pathogen invasion and inducing the host’s immune response. This study aimed to explore the
prognostic value of TLR2 and TLR4 tumor expressions in colorectal cancer patients. We studied the immunohistochemical
expressions of TLR2 and TLR4 using tissue microarray specimens from 825 patients undergoing surgery in the Department of
Surgery, Helsinki University Hospital, between 1982 and 2002. We assessed the relationships between TLR2 and TLR4
expressions and clinicopathological variables and patient survival. We generated survival curves using the Kaplan-Meier method,
determining significance with the log-rank test. Among patients with lymph node–positive disease and no distant metastases
(Dukes C), a strong TLR2 immunoactivity associated with a better prognosis (p < 0.001). Among patients with local Dukes B
disease, a strong TLR4 immunoactivity associated with a worse disease-specific survival (DSS; p = 0.017). In the multivariate
survival analysis, moderate TLR4 immunoactivity compared with strong TLR4 immunoactivity (hazard ratio (HR) 0.66, 95%
confidence interval (CI) 0.49–0.89, p = 0.007) served as an independent prognostic factor. In the multivariate analysis for the
Dukes subgroups, moderate TLR2 immunoactivity (HR 2.63, 95% CI 1.56–4.44, p < 0.001) compared with strong TLR2
immunoactivity served as an independent negative prognostic factor in the Dukes C subgroup. TLR2 and TLR4 might be new
prognostic factors to indicate which CRC patients require adjuvant therapy and which could spare from an unnecessary follow-
up, but further investigations are needed.
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Abbreviations
TLR Toll-like receptor
TLR2 Toll-like receptor 2








SIR Systemic inflammatory response
DSS Disease-specific survival
DC Dendritic cell
MyD88 Myeloid differentiation primary response gene 88
IBD Inflammatory bowel disease
NF- B Nuclear factor B
Introduction
Colorectal cancer (CRC) represents a major burden for public
healthcare systems as the third most common malignancy
globally and the second leading cause of cancer deaths. In
2018, more than 1.8 million new cases were diagnosed and
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881,000 CRC deaths occurred [1]. A wide geographical dif-
ference in CRC burden exists, with a threefold higher inci-
dence and about 55% of all deaths occurring in transitioning
countries [1–3]. The CRC burden is expected to increase giv-
en the aging and growth of populations and the adoption of a
so-called Western lifestyle [3].
CRC survival in developed countries has increased given
improved screening and treatment, although 17% of stage II
and 36% of stage III tumors still recur within 5 years.
Identifying patients that need thorough follow-up and adju-
vant therapy remains important, whereas other patients could
be spared unnecessary treatment and possibly follow-up [4].
Chronic inflammation serves as an important risk factor for
cancer. Both the local tumor microenvironment (TME) and
the systemic host response play crucial roles in the develop-
ment and progression of cancer [5, 6]. Reports have indicated
that the host’s systemic inflammatory response (SIR), evi-
denced by an elevated preoperative C-reactive protein (CRP)
value, predicts a shorter survival period among patients un-
dergoing primary tumor resection [7, 8]. Yet, local inflamma-
tion found specifically in the invasive area of the tumor pre-
dicts better survival [9].
Toll-like receptors (TLR) represent a large family of pattern
recognition receptors expressed on immune cells and epithe-
lial cells and play a crucial role in the innate immune response
since they detect pathogens and induce pro-inflammatory im-
mune responses [5, 10–12]. Yet, TLR expression patterns vary
across different immune cells. In endothelial cells, for exam-
ple, TLR2 and TLR4 express intracellularly, whereas, in leu-
kocytes such as monocytes, macrophages, neutrophils, den-
dritic cells (DCs), and natural killer (NK) cells, TLR2 and
TLR4 expressed on the cell membranes [13].
TLRs work through the myeloid differentiation primary
response gene 88 (myD88) pathway common to all TLRs.
Furthermore, TLR3 and TLR4 work through the myD88-
independent pathways [5, 10–12]. Additionally, TLRs induce
the maturation of DCs leading to T cell activation and differ-
entiation into effector cells, necessary for initiating an adap-
tive immune response. Thus, TLR signaling represents an
important link between the host’s innate and adaptive immune
responses [10, 14, 15].
Alongside exogenous microbial ligands, TLRs also recog-
nize several endogenous host-derived ligands released during
tissue damage and tumor progression [5, 10–13]. TLRs are
also known to take part in the pathogenesis of several autoim-
mune, chronic inflammatory, and infectious diseases includ-
ing rheumatoid arthritis [16], type 1 and 2 diabetes [17, 18],
psoriasis [10], Crohn’s disease [19], and ulcerous colitis [20].
Several studies showed that TLRs play a role in cancer
pathogenesis. TLRs express on tumor cells, while dying tumor
cells release endogenous TLR ligands, thus activating TLR
signaling and promoting tumorigenesis [21–23]. It is thought
that different TLRs carry specific and different protumoral
and/or antitumoral roles in different tumors [12]. In relation
to CRC, no prognostic value has been found for TLR2, while
contradictory results have emerged for TLR4 [24–27].
Therefore, this study aimed to clarify the prognostic roles of
TLR2 and TLR4 in colorectal cancer.
Materials and methods
Patients
Our cohort consisted of 825 patients undergoing a primary
operation for CRC at the Department of Surgery, Helsinki
University Hospital, between 1982 and 2002. Among these
patients, 457 (55.4%) were male. The median age was
67.5 years (interquartile range (IQR) 57.6–75.3 years). The
tumor was located in the rectum in 401 (48.6%) patients and
in the colon in 424 (51.4%) patients.
The median follow-up time was 5.1 years (IQR 1.2–17.2)
and 641 (77.7%) patients died by the end of the follow-up
period. The 5-year disease-specific survival (DSS) was
58.9% (95% confidence interval (CI) 55.4–62.4). Among
right-sided cancer patients, 5-year DSS rates were 58.1%
(95% CI 51.4–64.8) and 59.2% (95% CI 55.1–63.3) among
left-sided cancer patients. Among 292 stage 2 patients, 25
(8.6%) received adjuvant therapy, while 53 (23.6%) of 225
stage 3 patients received adjuvant therapy, and 62 of 186
(33.3%) stage 4 patients received adjuvant therapy.
At the time of patient recruitment, we used the modified
Dukes staging for CRC in our clinic. As such, 122 cases tumor
were classified as Dukes stage A (14.8%), 292 cases as Dukes
B (35.4%), 225 as Dukes C (27.3%), and 186 as Dukes D
(22.5%). Table 1 summarizes the patients’ clinicopathological
characteristics.
We received the clinical data from patients’ medical re-
cords and the survival data and causes of death from the
Population Register Center of Finland and Statistics Finland.
The Surgical Ethics Committee of Helsinki University
Hospital (Dnro HUS 226/E6/06, extension TMK02 §66
17.4.2013) approved the study protocol. The National
Supervisory Authority of Health and Welfare granted permis-
sion to use tissue archive samples retrospectively without re-
quiring individual consent (Valvira Dnro 10041/06.01.03.01/
2012).
Tissue samples
Surgical tumor samples fixed in formalin and embedded in
paraffin were stored in the archives of the Department of
Pathology at the University of Helsinki. Histopathologically
representative areas of the tumor samples were marked on
hematoxylin- and eosin-stained slides by an experienced pa-
thologist (JH). From the annotated areas, three 1.0-mm cores
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were punched from each tumor and embedded in a recipient
paraffin block with a semiautomatic tissue arrayer (Beecher
Instruments Inc., Silver Spring, MD, USA). Sections of 4 μm
were cut from the tissue microarray (TMA) blocks for
immunohistochemistry.
Immunohistochemistry
Slides with TMA block sections were deparaffinized in xylene
and then rehydrated in solutions containing a decreasing con-
centration of ethanol, beginning with pure alcohol and ending
with distilled water. The antigen retrieval was accomplished
by treating the slides in a PreTreatment module (Lab Vision
UK Ltd., UK) in a Tris-HCl buffer (pH 8.5) for 20 min at
98 °C.
Staining of the slides was carried out in an Autostainer 480
(Lab Vision, Fremont, CA, USA) using the REAL EnVision
Detection System (peroxidase/DAB+, rabbit/mouse; Dako,
Glostrup, Denmark). The inactivation of endogenous peroxi-
dases was completed by incubating the slides in 0.3% hydro-
gen peroxide for 5 min. Subsequently, the primary incubation
with rabbit polyclonal antibodies against TLR4 (H-80; Santa
Cruz Biotechnology, Santa Cruz, CA, USA; diluted to 1:50)
or TLR2 (H-175; Santa Cruz Biotechnology, Santa Cruz, CA,
USA; diluted to 1:50) was carried out for 1 h, followed by
incubation with the Dako REAL EnVision/HRP detection
system using the Rabbit (ENV) reagent for 30 min. Finally,
stainings were visualized using the Dako REAL DAB+
Chromogen for 10 min. Between each step, the slides were
washed in PBS 0.04% Tween20. Slides were counterstained
with Meyer’s hematoxylin and finally mounted in Pertex
Mounting (Histolab Products AB, Sweden). Tissues showing
a high immunoreactivity for these antigens were used as the
positive controls (tonsillar and gums). Specimens processed
without any primary antibody were used as the negative con-
trols. We have compared the results of TLR4 stainings of a
small cohort with the new TLR4 mouse monoclonal antibody
(sc-293072, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), the immunoexpression of TLR4 by the two different
antibodies correlated (rs = 0.721, p < 0.001, Spearman’s rank
correlation test).
Scoring
Two researchers (IB-L and JH) independently scored the
TLR2 and TLR4 immunostainings. TLR2 and TLR4
immunopositivity was defined as a brown cytoplasmic color
in the tumor cells scored from 0 to 3 reflecting the staining
intensity. Here, 0 represented negative staining and no
immunoac t iv i ty, 1 represen ted a weak pos i t ive
immunoactivity, 2 represented a moderate intensity of stain-
ing, and 3 represented a strong intensity of staining (Fig. 1). If
three scores of the same patient were different, the highest
score was used. The scores of both researchers were com-
pared, and cases with any variance were assigned a final score
reached through consensus.
Statistical analysis
For the statistical analysis, we grouped TLR2 and TLR4
immunoexpressions into low (0), moderate (1–2), and high
(3) expression levels. The associations between the TLR2
and TLR4 scoring and clinicopathological variables were an-
alyzed used the chi-square test. DSS was calculated from the
day of surgery to death from CRC. Survival curves were cal-
culated using the Kaplan-Meyer method and the p values were
calculated using the log-rank test.
For the univariate and multivariate survival analyses, we
used the Cox proportional hazards model, adjusting the mul-
tivariate analysis for the tumor stage, differentiation, and lo-
cation. The Cox model assumption of constant hazard ratios
over time was tested through the inclusion of a time-
dependent covariate separately for each variable tested.
A time-dependent variable was included for stage D, loca-
tion, and differentiation to fulfill the Cox assumption. We also
Table 1 Characteristics of colorectal cancer patients
Patient characteristics n (%)
Age
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considered interaction terms, finding no significant interac-
tions in the TLR4 model, although the TLR2 model identified
a significant interaction between stage C and TLR2
immunoexpression. Thus, we performed a separate analysis
for stage C patients.
We considered p < 0.05 as statistically significant and ap-
plied two-tailed tests. All statistical analyses were performed
using SPSS version 24.0 (IBM SPSS Statistics, version 24.0
for Mac; SPSS, Inc., Chicago, IL, USA).
Results
Immunostaining for TLR2
Among 825 CRC tumor samples, interpreting the TLR2 im-
munostaining proved successful in 775 (93.9%) samples. The
immunostaining of TLR2 was not possible to interpret appro-
priately in 6.1% of patients due to technical staining problems
or due to missing cancer tissue.
TLR2 s t a ined even ly in the cy top l a sm. The
immunopositivity was scored as strong in 200 (25.8%) sam-
ples, moderate in 313 (40.4%), and weak in 209 (27.0%), and
no immunopositivity was identified in 53 (6.8%) samples. In
the statistical analysis, patients fell into three groups, scored as
0 (negative), 1–2 (mild andmoderate), and 3 (high; Fig. 1a–d).
Immunostaining for TLR4
TLR4 stained evenly in the cytoplasm of 769 (93.2%) samples.
The immunostaining of TLR4 was not possible to interpret in
6.8% of patients for reasons mentioned above for TLR2. The
immunopositivity was scored as strong in 101 (13.1%) sam-
ples, moderate in 358 (46.6%), weak in 273 (35.5%), and no
immunopositivity was identified in 37 (4.8%) samples. Here,
patients fell into three groups, scored as 0 (negative), 1–2 (mild
and moderate), and 3 (high; Fig. 1e–h).
Association with clinicopathological parameters
Table 2 summarizes the relationships between the clinicopath-
ological variables and TLR2 immunointensity, while Table 3
provides the relationships with the TLR4 immunointensity.
TLR2 associated with the tumor location (p = 0.042) and the
tumor grade (p = 0.004, chi-square test, Table 2). TLR4 asso-
ciated with gender (p = 0.006) and the tumor grade (p < 0.001,
chi-square test, Table 3). Neither TLR2 nor TLR4
dba c
hge f
Fig. 1 Images of TLR2 and TLR4 immunohistochemistry stainings
representing colorectal cancer tumors with negative (a, e), weak (b, f),
moderate (c, g), and strong (d, h) staining. Images a–d are stained with a
TLR2 polyclonal antibody and images e–h are stained with a TLR4
polyclonal antibody. Original magnification × 20
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immunoexpression associated with patient age, the histologi-
cal type of tumor, or the Dukes tumor stage.
Survival analysis
In the DSS analysis, we found no difference between the dif-
ferent TLR2 (p = 0.199, log-rank test) or TLR4 expression
groups (p = 0.240, log-rank test; data not shown).
In the subgroup analysis, TLR2 emerged as a prognostic
factor among the Dukes C patients, that is, those with lymph
node–positive but distant metastasis–free disease (Fig. 2c;
p < 0.001, log-rank test). In this subgroup, the 5-year DSS
was 68.4% (95% CI 42.7–94.1) among patients with a nega-
tive TLR2 immunostaining and 72.6% (95% CI 60.6–84.6)
among those with a strong TLR2 immunostaining compared
with 48.2% (95% CI 39.2–57.3) among patients with a mod-
erate TLR2 immunostaining. Among the subgroups, Dukes A
(Fig. 2a), B (Fig. 2b), and D (Fig. 2d) patients, TLR2 did not
serve as a prognostic factor.
By contrast, TLR4 immunostaining served as a negative
prognostic factor among Dukes B patients (Fig. 3b; p =
0.017, log-rank test). A 5-year DSS reached 100% among
TLR4-negative patients, 80.6% (95% CI 75.1–86.1) among
TLR4-moderate patients, and 66.1% (95% CI 51.0–81.2)
among TLR4-strong immunostaining patients. Among the
Dukes A (Fig. 3a), Dukes C (Fig. 3c), and Dukes D (Fig.
3d) subgroups, TLR4 did not serve as a prognostic factor.
In the subgroup analysis among patients who did not re-
ceive adjuvant therapy, the results mirrored those among the
entire cohort. Among Dukes C patients who did not receive
adjuvant therapy, a very strong TLR2 expression predicted a
better survival compared with those patients with a moderate
TLR2 expression (Suppl. Fig. 2c; p < 0.001, log-rank test).
Among Dukes B patients who did not receive adjuvant thera-
py, a strong TLR4 immunoexpression showed a worse prog-
nosis (Suppl. Fig. 3b; p = 0.01, log-rank test). In the Cox uni-
variate survival analysis, patients over 65 years of age (p =
0.001), patients with less differentiated cancer (p = 0.001), and
patients with higher Dukes stages (p < 0.001) exhibited worse
prognoses. In the Cox multivariate survival analysis adjusted
for age, gender, Dukes stage, the tumor grade, and tumor
location, a moderate TLR4 immunoreactivity (HR 0.66,
Table 2 Association between
TLR2 immunointensity and
clinicopathological parameters
among colorectal cancer patients
Clinicopathological variable n TLR p value1
0 1 and 2 3
n (%) n (%) n (%)
Age
< 65 330 23 (7.0) 217 (65.8) 90 (27.3) 0.701
≥ 65 445 30 (6.7) 305 (68.5) 110 (24.7)
Gender
Male 428 29 (6.8) 296 (69.2) 103 (24.1) 0.452
Female 347 24 (6.9) 226 (65.1) 97 (28.0)
Side
Right 217 19 (8.8) 138 (63.6) 60 (27.6) 0.266
Left 558 34 (6.1) 384 (68.8) 140 (25.1)
Location
Colon 403 28 (6.9) 256 (63.5) 119 (29.5) 0.042
Rectum 372 25 (6.7) 266 (71.5) 81 (21.8)
Histological type
Adeno 689 42 (6.1) 467 (67.8) 180 (26.1) 0.058
Mucinous 85 11 (12.9) 55 (64.7) 19 (22.4)
Dukes stage
A 110 12 (10.9) 76 (69.1) 22 (20.0) 0.537
B 279 16 (5.7) 189 (67.7) 74 (26.5)
C 210 14 (6.7) 139 (66.2) 57 (27.1)
D 176 11 (6.3) 118 (67.0) 47 (26.7)
Tumor grade (WHO)
1 24 5 (20.8) 11 (45.8) 8 (33.3) 0.004
2 529 33 (6.2) 356 (67.3) 140 (26.5)
3 189 9 (4.8) 135 (71.4) 45 (23.8)
4 31 6 (19.4) 18 (58.1) 7 (22.6)
TLR2, Toll-like receptor 2
1 Chi-square test
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95% CI 0.49–0.89, p = 0.007) compared with a strong TLR4
tumor expression served as an independent prognostic factor
(Table 4). In the Cox multivariate analysis including the same
clinicopathological parameters and TLR2, the TLR2 immu-
noreactivity did not serve as prognostic factor (data not
shown). In the Cox multivariate analysis for the Dukes C
subgroup, a moderate TLR2 immunoactivity (HR 2.63, 95%
CI 1.56–4.44, p < 0.001) compared with a strong TLR2 im-
munoreactivity served as an independent negative prognostic
factor (Table 5). In the Cox multivariate analysis, adjuvant
therapy did not serve as prognostic factor (Suppl. Table 1,
p = 0.747).
Discussion
Among CRC patients with lymph node metastases but no
distant metastases (Dukes C), a very strong expression of
TLR2 predicted a remarkably better survival compared with
those patients with a moderate expression. Among patients
with a Dukes B tumor, a strong TLR4 immunoexpression
indicated a worse prognosis. A survival analysis among pa-
tients who did not receive adjuvant therapy revealed similar
results. A strong TLR4 expression in the tumor served as an
independent prognostic factor.
CRC patients with tumors that have progressed to regional
lymph nodes or metastasized to other organs are typically treated
with postoperative chemotherapy. However, a portion of such
patients still die from recurrent disease. Yet, some patients with
lymph node–positive disease survive cancer without adjuvant
treatment and some patients with seemingly local disease die
from recurrent disease. Thus, discussions in the literature contin-
ue regarding which patients should receive adjuvant therapy and
which may be spared therapy [4, 28]. Here, we have identified a
potential role for prognostic biomarkers such as TLRs.
A recent study investigated the roles of TLR2 and TLR4 in
118 CRC patients [24]. Among such patients, the intensity and
extent of staining were studied separately in the tumor, the




Clinicopathological variable n TLR4 p value1
0 1 and 2 3
n (%) n (%) n (%)
Age
< 65 323 20 (6.2) 264 (81.7) 39 (12.1) 0.204
≥ 65 443 16 (3.6) 365 (82.4) 62 (14.0)
Gender
Male 428 28 (6.5) 354 (82.7) 46 (10.7) 0.006
Female 341 9 (2.6) 277 (81.2) 55 (16.1)
Side
Right 214 13 (6.1) 177 (82.7) 24 (11.2) 0.4
Left 555 24 (4.3) 454 (81.8) 77 (13.9)
Location
Colon 404 18 (4.59) 330 (81.7) 56 (13.9) 0.748
Rectum 365 19 (5.2) 301 (82.5) 45 (12.3)
Histological type
Adeno 689 29 (4.2) 570 (82.7) 90 (13.1) 0.061
Mucinous 79 8 (10.1) 60 (75.9) 11 (13.9)
Dukes stage
A 114 9 (7.9) 90 (78.9) 15 (13.2) 0.342
B 273 8 (2.9) 223 (81.7) 42 (15.4)
C 208 11 (5.3) 175 (84.1) 22 (12.6)
D 174 9 (5.2) 143 (82.2) 22 (12.6)
Tumor grade (WHO)
1 25 1 (4.0) 22 (88.0) 2 (8.0) < 0.001
2 528 23 (4.4) 431 (81.6) 74 (14.0)
3 185 5 (2.7) 158 (85.9) 21 (11.4)
4 30 8 (26.7) 19 (63.3) 3 (10.0)
TLR4, Toll-like receptor 4
1 Chi-square test
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invasive border, the normal mucosa, and lymph node metastases
if present. TLR4 expression was significantly stronger in the
normal mucosa and in lymph node metastases compared with
that in the tumor. The opposite emerged for TLR2 expression,
which increased in carcinoma cells and stained at a weaker in-
tensity in the lymph nodes than in the bulk and invasive front of
the tumor. In that study in contrast to our findings here, re-
searchers found no significant association between TLR2 and
TLR4 tumor expressions and patient survival. In their study,
TLR2 and TLR4 were expressed in all tumors, whereas in our
series, a few tumors lacked TLR expression.
In another study, Nihon-Yanagi et al. found a higher TLR2
expression in cancer samples at each stage compared with that
in the normal mucosa [26]. Furthermore, TLR2 was more
intensively expressed in stage II and III tumors. In their study,
TLR4 expression in carcinoma tissues mirrored that in the
normal mucosa. The discrepancy between these findings and
our results may be explained by their smaller patient sample
size (n = 50), the different detection methods, and the different
antibodies used. For instance, Nihon-Yanagi et al. studied the
TLR4 and TLR2 expressions using real-time PCR and TLR
immunoexpression from whole sections, whereas we used
TMA slides and immunohistochemistry alone.
Additionally, Eiró et al. found that a high TLR4 expression in
CRC tumor cells relates to a lower recurrence rate [29]. Our
findings did not agree with this result. While we used the same
antibody, we found that a strong TLR4 expression predicted a
worse prognosis in lymph node–negative disease. Eiró et al. re-
ported 63Dukes B diseased patients from a patient cohort of 104.
Additionally, they report of 70 lymph node–positive patients
from the same cohort of 104, a figure which appears somewhat
problematic. In their study, TLR4 positivity was located on the
cell membranes, whereas we found cytoplasmic expression.
In another study, Siminatonaki et al. usingWestern blot and
immunohistochemistry found a positive correlation between
TLR4 downregulation and the occurrence of lymphogenous
and hematogenous metastases in 115 CRC patients [27]. In
our study, however, among Dukes B patients, TLR4 overex-
pression indicated a worse prognosis, although among Dukes
C and D tumors, we found no significant relationship.
Siminatonaki et al. additionally reported a TLR4 positivity
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14     8        6      6       5       0       0    
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11      2       2       1       0       0       0  
118    7       6       4       2       1       0       
47     4       1        0       0      0       0       
Fig. 2 Disease-specific survival analysis of TLR2 in colorectal cancer patients using the Kaplan-Meier method. aDukes A, bDukes B, cDukes C, d and
Dukes D patients. The log-rank test was used
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observed immunopositivity primarily in the cytoplasm, de-
spite using the same antibody.
TLR signaling plays an important role in different cancers
and the role of TLR expression can apparently vary between
different cancers [12]. In Barrett’s metaplasia, the TLR4 pro-
tein expression appears upregulated, with the expression in-
tensity correlating with a poor prognosis and with the degree
of dysplasia in esophageal squamous cell carcinoma develop-
ment [30]. During the early stage of oral tongue squamous cell
carcinoma, TLR2 and TLR4 expressions serve as predictive
markers of invasive tumor growth and a higher tumor grade
[31]. The nuclear TLR2 expression level can predict tumor
recurrence and neck metastases of tongue cancer [32].
Previous studies demonstrated that, in pancreatic ductal ade-
nocarcinoma, TLR2 and TLR4 serve as positive predictors of
prognosis in stage I and II disease and in patients with small-
size tumors [33]. In murine and human gastric tumors, TLR2
appears upregulated and associates with a poorer overall sur-
vival in humans [34].
An increased TLR4 expression has been associated with tu-
mor size and distant metastases in breast cancer [35], a higher
recurrence rate in prostate cancer [36], and a poorer overall
survival rate in ovarian cancer [37]. Additionally, an increased
TLR4 expression associated with a shorter relapse-free survival
time in cutaneous malignant melanomas [25], a poorer differen-
tiation state in lung cancer [38], and a larger tumor size in murine
experimental melanoma lung metastases [39]. Interestingly, in
follicular thyroid neoplasms, both the downregulation and upreg-
ulation of TLR4 have been connected to primary metastases and
the aggressiveness of cancer, whereas TLR2 expression associ-
ated with no clinicopathological parameter [40].
Based on our findings, a very strong TLR2 expression served
as a positive prognostic factor among patients with lymph node–
positive disease (Dukes C stage). Additionally, patients who had
a negative TLR2 expression exhibited a better DSS than patients
with moderate TLR staining, although the number of patients
with a negative TLR2 expression in the Dukes C subgroup
was too small to draw any definitive conclusions. To our knowl-
edge, this favorable TLR2 prognostic role in CRC has not been
previously reported. TLR2 signaling may generate both pro-
inflammatory and anti-inflammatory responses. The interaction
between TLR2 and different co-receptors such as TLR1, TLR6,
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Fig. 3 Disease-specific survival analysis of TLR4 in colorectal cancer patients using the Kaplan-Meier method. aDukes A, bDukes B, cDukes C, d and
Dukes D patients. The log-rank test was used
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We found that a strong TLR4 immunoreactivity predicts a
worse prognosis in patients with a local colorectal tumor.
More interestingly, among patients in the subgroups of
Dukes A and B tumors (patients with no lymph node metas-
tases), none of the patients lacking TLR4 expression in the
tumor died from the disease. The number of patients in these
subgroups was, however, quite small, such that further studies
on larger cohorts are necessary.
Finding biomarkers remains pivotal in order to detect high-
risk disease and to identify patients requiring adjuvant therapy.
Our findings suggest that a strong TLR4 immunopositivity could
identify those stage II patients requiring adjuvant therapy. A
negative TLR4 immunostaining, however, could possibly spare
some lower stage patients from unnecessary follow-up. In lymph
node–positive disease, both a negative and a very strong TLR2
expression might serve as a predictive marker to identify patients
that could be spared from adjuvant therapy.
The strength of our work lies in the large and well-
characterized patient cohort, which allowed us to focus on differ-
ent stage subgroups. The follow-up time in this cohort is also
rather long, which allowed us to determine if patients were gen-
uinely cured of cancer. On the other hand, the cohort is quite old.
One strength to using an older cohort lies in the less frequent
administration of adjuvant therapy at that time, whereby we can
observe a more natural course of disease following surgery.
Moreover, one drawback to using an older cohort lies in the
harvesting of lymph nodes from surgical specimens, which relied
on significantly inferior practices than those used today. In older
series, thus, there might be a small migration of stage [42].
Unsurprisingly, surgical techniques have changed somewhat
and operations along embryological planes, total mesorectal ex-
cision (TME), and complete mesocolic excision (CME) now
represent standard procedures in CRC surgery [43, 44].
Another disadvantage to using an older cohort lies in the different
staging classifications used at that time compared with the stag-
ingmethods currently employed. The TMA technique allows the
Table 4 Univariate and
multivariate Cox regression
analysis for disease-specific sur-
vival of colorectal cancer patients
Univariate analysis p value1 Multivariate analysis p value1
Hazard ratio 95% CI Hazard ratio 95% CI
Age
< 65 1.00 1.00
≥ 65 1.42 1.14–1.75 0.001 1.91 1.52–2.40 < 0.001
Gender
Male 1.00 1.00
Female 0.96 0.78–1.18 0.71 1.4 0.91–1.42 0.248
Dukes stage
A 1.00 1.00
B 2.13 1.35–4.2 0.005 2.33 1.32–4.09 0.003
C 5.3 3.74–11.2 < 0.001 6.46 3.74–11.17 < 0.001
D 38.24 23.9–83.1 < 0.001 44.62 23.9–83.3 < 0.001
Tumor grade (WHO)
1–2 1.00 1.00
3–4 2.49 1.81–3.43 0.001 2.13 1.52–3.0 < 0.001
Location
Colon 1.00 1.00
Rectum 1.16 1.06–1.27 0.001 0.87 0.64–1.2 0.416
TLR4
Strong 1.00 1.00
Moderate 0.8 0.59–1.07 0.127 0.66 0.49–0.89 0.007
Negative 0.67 0.37–1.24 0.202 0.67 0.36–1.25 0.206
Multivariate analysis included adjustments for gender, age, Dukes stage, and tumor grade
TLR4, Toll-like receptor 4; CI, confidence interval
Table 5 Multivariate Cox regression analysis for disease-specific sur-
vival of Dukes C subgroup colorectal cancer patients
TLR2 expression Hazard ratio 95% CI p value1
Strong 1.00
Moderate 2.63 1.56–4.44 < 0.001
Negative 1.26 0.47–3.4 0.646
Multivariate analysis included adjustment for gender, age, Dukes stage,
and tumor grade
TLR2, Toll-like receptor 2; CI, confidence interval
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analysis of a large patient cohort, although inadequate represen-
tation of the whole tissue section might represent a limitation of
this technique. By punching multiple areas of the primary tumor,
however, we minimize this limitation [45].
Conclusions
To our knowledge, this represents the first study to report a pre-
dictive role of TLR2 inCRC.A strong TLR2 immunoexpression
served as a positive prognostic factor in lymph node–positive
CRC patients. A strong TLR4 immunoexpression, however, pre-
dicted a worse prognosis in patients with local CRC. In particu-
lar, none of the patients with a local, TLR4-negative tumor died
from the disease. Further investigations are necessary in order to
validate these findings.
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